The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

aclarubicin     methyl(1R,2R,4S)-4-[4- dimethylamino-5-[4...

Synonyms: SureCN1649619, CHEBI:170281, NINDS_000678, NSC-208734, NSC-240619, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Aclacinomycin A


High impact information on Aclacinomycin A


Chemical compound and disease context of Aclacinomycin A


Biological context of Aclacinomycin A


Anatomical context of Aclacinomycin A


Associations of Aclacinomycin A with other chemical compounds


Gene context of Aclacinomycin A


Analytical, diagnostic and therapeutic context of Aclacinomycin A


  1. Combined cytotoxicity effect of hyperthermia and anthracycline antibiotics on human tumor cells. Ohnoshi, T., Ohnuma, T., Beranek, J.T., Holland, J.F. J. Natl. Cancer Inst. (1985) [Pubmed]
  2. Aclacinomycin A in acute leukaemias and lymphomas. Mathé, G., Gescher, F., Bayssas, M., Misset, J.L., Machover, D., Gil, M.A., Delgado, M., Ribaud, P., Hayat, M. Lancet (1979) [Pubmed]
  3. Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. Rowe, J.M., Chang, A.Y., Bennett, J.M. Blood (1988) [Pubmed]
  4. Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity. Marsh, J.C., Brown, B.J., Nierenburg, M.M. Cancer Res. (1983) [Pubmed]
  5. Effects on leukemic clonogenic cells in murine myeloid leukemia of 1-beta-D-arabinofuranosylcytosine and the anthracyclines adriamycin, daunomycin, aclacinomycin A, and 4'-epidoxorubicin. Nara, N., Yamashita, Y., Murohashi, I., Tanikawa, S., Imai, Y., Aoki, N. Cancer Res. (1987) [Pubmed]
  6. Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells. Aries, A., Trentesaux, C., Ottolenghi, S., Jardillier, J.C., Jeannesson, P., Doubeikovski, A. Blood (1996) [Pubmed]
  7. Effects of aclacinomycin-A on murine leukemia. Nara, N., Miyamoto, T., Hirashima, K., Momoi, H. Blood (1982) [Pubmed]
  8. Enhanced activity of peritoneal cells after aclacinomycin injection: effect of pretreatment with superoxide dismutase on aclacinomycin-induced cytological alterations and antitumoral activity. Bravo-Cuellar, A., Balercia, G., Levesque, J.P., Liu, X.H., Osculati, F., Orbach-Arbouys, S. Cancer Res. (1989) [Pubmed]
  9. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Watanabe, M., Komeshima, N., Nakajima, S., Tsuruo, T. Cancer Res. (1988) [Pubmed]
  10. Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma. Louie, K.G., Hamilton, T.C., Behrens, B.C., Grotzinger, K.R., McKoy, W.M., Myers, C.E., Young, R.C., Ozols, R.F. Cancer Chemother. Pharmacol. (1986) [Pubmed]
  11. Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Saito, T., Takehara, M., Tanaka, R., Lee, R., Horie, M., Wataba, K., Ito, E., Kudo, R. Gynecol. Oncol. (2004) [Pubmed]
  12. Assessment of the antiinvasive potential of the anthracycline aclacinomycin (Aclarubicin) in a human fibrosarcoma cell line. Addadi-Rebbah, S., Poitevin, S., Fourre, N., Polette, M., Garnotel, R., Jeannesson, P. Int. J. Oncol. (2004) [Pubmed]
  13. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns. Tsuruo, T., Kawabata, H., Nagumo, N., Iida, H., Kitatani, Y., Tsukagoshi, S., Sakurai, Y. Cancer Chemother. Pharmacol. (1985) [Pubmed]
  14. Uptake, efflux, and hydrolysis of aclacinomycin A in Friend leukemia cells. Fourcade, A., Farhi, J.J., Bennoun, M., Tapiero, H. Cancer Res. (1982) [Pubmed]
  15. Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells. Traganos, F., Staiano-Coico, L., Darzynkiewicz, Z., Melamed, M.R. Cancer Res. (1981) [Pubmed]
  16. Enhanced activity of murine peritoneal cells after aclacinomycin injection: characteristics of the enhanced respiratory burst. Bravo-Cuellar, A., Homo-Delarche, F., Cabannes, J., Orbach-Arbouys, S. Cancer Res. (1988) [Pubmed]
  17. Tumorigenicity in vivo and induction of mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: structure-activity relationship and predictive value of short-term tests. Westendorf, J., Marquardt, H., Ketkar, M.B., Mohr, U., Marquardt, H. Cancer Res. (1983) [Pubmed]
  18. Enhanced activity of mouse peritoneal cells after aclacinomycin administration. Cuellar, A.B., Algara, D.S., Metzger, G., Orbach-Arbouys, S. Cancer Res. (1987) [Pubmed]
  19. In vitro sensitivity of myeloblast clonogenic cells to doxorubicin, aclacinomycin A, and 4'-O-tetrapyranyl-doxorubicin: correlations with clinical responses. Georgoulias, V., Iskandar, Y.L., Amesland, F., Ribaud, P., Mathé, G., Jasmin, C. J. Clin. Oncol. (1984) [Pubmed]
  20. Differentiation of WEHI-3B D+ monomyelocytic leukemia cells by retinoic acid and aclacinomycin A. Gamba-Vitalo, C., Blair, O.C., Keyes, S.R., Sartorelli, A.C. Cancer Res. (1986) [Pubmed]
  21. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. Figueiredo-Pereira, M.E., Chen, W.E., Li, J., Johdo, O. J. Biol. Chem. (1996) [Pubmed]
  22. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Odaimi, M., Andersson, B.S., McCredie, K.B., Beran, M. Cancer Res. (1986) [Pubmed]
  23. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Doroshow, J.H. Cancer Res. (1983) [Pubmed]
  24. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Shiokawa, T., Hattori, Y., Kawano, K., Ohguchi, Y., Kawakami, H., Toma, K., Maitani, Y. Clin. Cancer Res. (2005) [Pubmed]
  25. Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains. Shelton, C.J., Harding, M.M., Prakash, A.S. Biochemistry (1996) [Pubmed]
  26. Nuclear transcription factor GATA-1 is activated during aclacinomycin-induced erythroid differentiation. Gillet, R., Bobichon, H., Trentesaux, C. Biol. Cell (2002) [Pubmed]
  27. Induction of differentiation in Friend-erythroleukemia cells by aclacinomycin A: early transient decrease in c-myc and c-myb mRNA levels. Schaefer, A., Dressel, A., Lingelbach, K., Schmidt, C.A., Steinheider, G., Marquardt, H. Leukemia (1992) [Pubmed]
  28. Increased expression of GATA-1 and NFE-2 erythroid-specific transcription factors during aclacinomycin-mediated differentiation of human erythroleukemic cells. Trentesaux, C., Nyoung, M.N., Aries, A., Morceau, F., Ronchi, A., Ottolenghi, S., Jardillier, J.C., Jeannesson, P. Leukemia (1993) [Pubmed]
  29. Studies on the susceptibility to NK-mediated lysis and the simultaneous expression of various surface molecules in anthracyclin-treated K562 cells and in four K562 cell clones. Benoist, H., Joly, P., Broglio, C., Jeannesson, P., Idoine, O., Dufer, J., Desplaces, A. Immunol. Lett. (1992) [Pubmed]
  30. Delivery of aclacinomycin A to human glioma cells in vitro by the low-density lipoprotein pathway. Rudling, M.J., Collins, V.P., Peterson, C.O. Cancer Res. (1983) [Pubmed]
  31. Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. Karanes, C., Young, J.D., Samson, M.K., Smith, L.B., Franco, L.A., Baker, L.H. Investigational new drugs. (1983) [Pubmed]
  32. Inhibition of amino acid uptake and incorporation into proteins in Friend erythroleukemia cells by the anthracycline antitumor antibiotic aclacinomycin A. Schaefer, A., Boldt, J., Westendorf, J., Steinheider, G., Marquardt, H. Biochem. Pharmacol. (1988) [Pubmed]
  33. Sensitive enzyme immunoassay for the quantification of aclacinomycin A using beta-D-galactosidase as a label. Sohda, M., Fujiwara, K., Saikusa, H., Kitagawa, T., Nakamura, N., Hara, K., Tone, H. Cancer Chemother. Pharmacol. (1985) [Pubmed]
WikiGenes - Universities